CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 8.49: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.68BCNY698.29M · vs all stocks (USD)
Revenue (TTM)
236.86MCNY35.34M · vs all stocks (USD)
Profit Margin
-78.26%vs Biotechnology peers
Beta
0.5920xvs all stocks
52-Week Change
41.94%vs all stocks
Market Capitalization
4.68BCNY698.29M · vs all stocks (USD)
Enterprise Value
4.64BCNY692.93M · vs all stocks (USD)
Price to Sales (TTM)
19.76xvs Biotechnology peers
Price to Book (MRQ)
5.25xvs Biotechnology peers
Enterprise to Revenue
19.61xvs Biotechnology peers
Enterprise to EBITDA
-143.32xvs Biotechnology peers
Gross Margin
16.48%vs Biotechnology peers
Profit Margin
-78.26%vs Biotechnology peers
Operating Margin
-41.62%vs Biotechnology peers
Return on Assets (TTM)
-3.89%vs Biotechnology peers
Return on Equity (TTM)
-18.85%vs Biotechnology peers
Revenue (TTM)
236.86MCNY35.34M · vs all stocks (USD)
Revenue per Share (TTM)
1.64CNYUpdated Sep 21, 2026Quarterly Revenue Growth
26.10%vs Biotechnology peers
Gross Profit (TTM)
68.04MCNY10.15M · vs all stocks (USD)
EBITDA (TTM)
-32.40MCNY-4.83M · vs all stocks (USD)
Net Income (TTM)
-185.38MCNY-27.66M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-19.03%vs Biotechnology peers
Operating Cash Flow (TTM)
-1.94MCNY-289.44K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-50.76MCNY-7.57M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
13.29MCNYFY2025 · Dec 31, 2025Revenue
225.27MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
155.29MCNYFY2025 · Dec 31, 2025Gross Profit
69.98MCNYFY2025 · Dec 31, 2025Operating Income
-85.60MCNY-12.77M · vs all stocks (USD)
Pre-tax Income
-208.48MCNYFY2025 · Dec 31, 2025Income Tax Expense
21.26MCNYFY2025 · Dec 31, 2025Net Income
-229.73MCNYFY2025 · Dec 31, 2025EBIT
-202.20MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-28.32MCNYFY2025 · Dec 31, 2025Research & Development
9.37MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
79.32MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.60MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.36MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
6.27MCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.57CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.57CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
144.80MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
144.80MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-229.73MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.39MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
21.16MCNYFY2025 · Dec 31, 2025Free Cash Flow
-45.93MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
127.19MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-229.73MCNYFY2025 · Dec 31, 2025Other Non-cash Items
7.38MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
165.64MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
77.87MCNYFY2025 · Dec 31, 2025Capital Expenditures
-67.08MCNYFY2025 · Dec 31, 2025Net Acquisitions
44.63MCNYFY2025 · Dec 31, 2025Other Investing Activity
-20.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-42.46MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
65.30MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-187.82MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-28.42MCNYFY2025 · Dec 31, 2025Other Financing Charges
-111.57KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-151.06MCNYFY2025 · Dec 31, 2025Shares Outstanding
144.79MSharesUpdated Sep 21, 2026Float Shares
36.85MSharesUpdated Sep 21, 2026% Held by Insiders
73.04%vs all stocks
% Held by Institutions
0.30%vs all stocks
Total Cash (MRQ)
195.11MCNY29.11M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.37CNYUpdated Sep 21, 2026Total Debt (MRQ)
234.37MCNY34.97M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2600xvs Biotechnology peers
Current Ratio (MRQ)
1.38xvs Biotechnology peers
Book Value per Share (MRQ)
6.15CNYUpdated Sep 21, 2026Total Assets
1.25BCNY186.71M · vs all stocks (USD)
Total Current Assets
383.25MCNYFY2025 · Dec 31, 2025Total Liabilities
327.50MCNYFY2025 · Dec 31, 2025Total Non-current Assets
867.98MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
142.08MCNYFY2025 · Dec 31, 2025Total Current Liabilities
185.42MCNYFY2025 · Dec 31, 2025Cash
137.10MCNYFY2025 · Dec 31, 2025Cash Equivalents
316.96KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
137.42MCNYFY2025 · Dec 31, 2025Other Short-term Investments
10.02MCNYFY2025 · Dec 31, 2025Accounts Receivable
109.36MCNYFY2025 · Dec 31, 2025Inventory
60.87MCNYFY2025 · Dec 31, 2025Accounts Payable
47.01MCNYFY2025 · Dec 31, 2025Short-term Debt
73.27MCNYFY2025 · Dec 31, 2025Other Current Liabilities
7.48MCNYFY2025 · Dec 31, 2025Long-term Debt
91.67MCNYFY2025 · Dec 31, 2025Common Stock (Book)
144.79MCNYFY2025 · Dec 31, 2025Retained Earnings
69.68MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
923.73MCNY137.84M · vs all stocks (USD)
Treasury Stock
50.00MCNYFY2025 · Dec 31, 202552-Week Low
20.30CNYUpdated Sep 21, 202652-Week High
40.22CNYUpdated Sep 21, 202652-Week Change
41.94%vs all stocks
Beta
0.5920xvs all stocks
50-Day MA
32.11CNYUpdated Sep 21, 2026200-Day MA
29.98CNYUpdated Sep 21, 2026Avg 10-Day Volume
2.41MSharesUpdated Sep 21, 2026Avg 30-Day Volume
3.20MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-1.28CNYUpdated Sep 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 8.49: safe zoneNotable
Altman Z-Score: 8.49
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Collegium Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Anglikang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ChemPartner Pharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Revenio Group Oyj
Tier 1ProductionApproval-Gated PipelineRule
Morepen Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Verastem Inc.
Tier 1ProductionApproval-Gated PipelineRule
Annexon, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Gen Ilac ve Saglik Urunleri A.S.
Tier 1ProductionApproval-Gated PipelineRule
XOMA Corporation
Tier 1ProductionApproval-Gated PipelineSenseMakingInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Suzhou Jinfu Technology Co., Ltd.
1 interpretationDown-Close Share With Multi-Year Earnings Decrease
Wintao Communications Co.
1 interpretationDown-Close Share With Multi-Year Earnings Decrease
Trs Information Technology Co.
1 interpretationDown-Close Share With Multi-Year Earnings Decrease